TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23532629
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (Epo-b) 30000 IU once weekly, increased to 30000 IU twice weekly if Hb increase was <0.5 g/dl after 4 weeks
Study: 20875231
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Tenofovir (TFV) + 200 mg Emtricitabine (FTC) + 300 mg Lamivudine (3TC) tablet formulation
Study: 24430001
Drug: Low-dose, transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, transdermal 17β-estradiol
Study: 22541797
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with TSOL16 and TSOL18 (200 μg each, plus 5mg Quil‐A)
Study: 12429158
Drug: Goserelin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin plus flutamide (G+F)
Study: 31343124
Drug: CXA-10 150
Normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-10 150 mg
Study: 31343124
Drug: CXA-10 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-10 (all doses)
Study: 30123047
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy at 658 nm
Study: 30123047
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy at 940 nm
Study: 30123047
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy at 808 nm
Study: 21044293
Drug: Annual effective
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual effective dose per capita for Japan
Study: 21044293
Drug: Annual collective
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual collective effective dose in Japan
Study: 17356942
Drug: Low-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fiber diet for 6 days preoperatively, followed by restoration of oral nutrition on postoperative day 3.
Study: 15863547
Drug: Isopropanolic black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropanolic black cohosh extract (40 mg daily for 12 weeks)
Study: 9228509
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.2 U/kg body weight)
Study: 9228509
Drug: U40 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: U40 insulin (0.2 U/kg body weight)
Study: 9228509
Drug: U100 soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: U100 soluble insulin
Study: 3476002
Drug: Supplemental ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental ascorbic acid 500 mg
Study: 3476002
Drug: Supplemental ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplemental ascorbic acid 1000 mg
Study: 2198977
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot methylprednisolone acetate (120 mg)
Study: 16481946
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV bolus of 500 mg of methylprednisolone
Study: 9232707
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for functional gastrointestinal disorders over a four-week period
Study: 8127946
Drug: d,l‐fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐fenfluramine (60 mg PO)
Study: 3609114
Drug: Endralazine 5
Normalized name: hydralazine hydrochloride 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine 5 mg administered before breakfast
Study: 3609114
Drug: Endralazine 5
Normalized name: hydralazine hydrochloride 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine 5 mg administered after breakfast
Study: 3609114
Drug: Endralazine 10
Normalized name: endralazine
DrugBank: Endralazine (DB13435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine 10 mg administered before breakfast
Study: 3609114
Drug: Endralazine 10
Normalized name: endralazine
DrugBank: Endralazine (DB13435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endralazine 10 mg administered after breakfast
Study: 23190184
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate (PO MTX) 25 mg
Study: 23190184
Drug: Subcutaneous Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous Methotrexate (SC MTX) 25 mg
Study: 15154115
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of rh-alpha GalA (agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly for 30-36 months
Study: 8095137
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment integrating both strategies from the start
Study: 25226322
Drug: Barbell deadlift
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barbell deadlift training (twice per week for 10 weeks)
Study: 21455716
Drug: CaD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaD group (800 mg calcium and 10 μg vitamin D(3), n = 26)
Study: 21455716
Drug: CaDK1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaDK1 group (800 mg calcium, 10 μg vitamin D(3), and 100 μg vitamin K(1), n = 26)
Study: 21455716
Drug: CaDK2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaDK2 group (800 mg calcium, 10 μg vitamin D(3), and 100 μg vitamin K(2), n = 24)
Study: 12617276
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (500 mg daily for five days with a 10-day tapering period)
Study: 30961947
Drug: Carvacrol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvacrol (1.2 mg/kg/day)
Study: 18201583
Drug: FDC ARV
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC ARV tablet for oral suspension (lamivudine 40 mg, nevirapine 70 mg, stavudine 10 mg)
Study: 18201583
Drug: Individual liquid
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual liquid formulations (lamivudine 10 mg/mL, nevirapine 50 mg/5 mL, stavudine 1 mg/mL)
Study: 11566069
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg) administered intravenously during dehydration
Study: 11566069
Drug: Dehydration effects
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydration effects on potassium and sodium excretion
Study: 9248869
Drug: Duloxetine hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine hydrochloride 20 mg daily for 6 weeks
Study: 7095604
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) and dihydroergotamine (DHE) combined treatment
Study: 26485439
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment at 14 cm H2 O
Study: 26485439
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment at 0 cm H2 O
Study: 16010540
Drug: 0.05 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 and 0.1 mg of pergolide (direct DA agonist)
Study: 16010540
Drug: 100 and
Normalized name: peg 100 and glyeryl stearates MISCELL FLAKES (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 and 200 mg of amantadine (indirect DA agonist)
Study: 10087750
Drug: Betamethasone‐cyclophosphamide pulse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone‐cyclophosphamide pulse (BCP) therapy
Study: 10087750
Drug: Azathioprine-corticosteroid treatment
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine-corticosteroid treatment
Study: 7836734
Drug: Captopril (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (150 mg/day for 3 days)
Study: 7836734
Drug: Nafamostat (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat (0.2 mg/kg per h) during exercise
Study: 3350283
Drug: Balloon distention
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon distention of the stomach with 100, 200, or 300 ml of water
Study: 3350283
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of lipid into the duodenum at 1.5 ml/min for 30 min
Study: 3350283
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of cholecystokinin-octapeptide intravenously at 20 ng/kg.h
Study: 18213383
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg daily for 12 months
Study: 8905428
Drug: Hydrocortisone 100
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 100 mg by intravenous infusion 60 min before extubation
Study: 8905428
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 3 cc)
Study: 1475621
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 7 days
Study: 1475621
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg for 7 days
Study: 30747613
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose on day 1, then 90 mg twice daily on days 2-30, plus open-label aspirin 300-325 mg on day 1, then 75-100 mg once daily on days 2-30.
Study: 30747613
Drug: Aspirin 300-325
Normalized name: aspirin 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300-325 mg on day 1, then 75-100 mg once daily on days 2-30 (control group).
Study: 26485203
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for osteoarthritis pain
Study: 26485203
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for osteoarthritis pain and insomnia
Study: 17542047
Drug: Quetiapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (mean daily doses 357-496 mg/day)
Study: 17542047
Drug: Haloperidol (10.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10.4 mg/day)
Study: 17542047
Drug: Risperidone (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (5.5 mg/day)
Study: 17542047
Drug: Chlorpromazine (552
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (552 mg/day)
Study: 16119514
Drug: Citalopram from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram from Eurofarma Laboratórios Ltda. (test formulation)
Study: 16119514
Drug: Cipramil from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipramil from Schering‐Plough (reference formulation)
Study: 12151431
Drug: Cetrorelix (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (0.25 mg to 0.5 mg)
Study: 11225793
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy plus dual chamber pacemaker programmed to optimal AV delay (Group 2)
Study: 11225793
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (Group 1)
Study: 7203001
Drug: Home-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based intervention program with nine months of weekly home visits
Study: 28972083
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B with GM-CSF
Study: 28972083
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B without GM-CSF
Study: 28972083
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B with or without GM-CSF
Study: 17043959
Drug: Compound branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound branch chain amino acid injection
Study: 17043959
Drug: Compound amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound amino acid (control)
Study: 14728606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sulfadoxine-pyrimethamine and Chloroquine (SP+CQ)
Study: 11766084
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PAN)
Study: 9266287
Drug: Angipress (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angipress (50 mg)
Study: 3822681
Drug: Propranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3 mg/kg/d)
Study: 29934286
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise intervention with telemonitoring guidance (weekly emails or phone calls)
Study: 27373088
Drug: Budesonide treatment
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide treatment (1 ml budesonide suspension in gelatin sponges)
Study: 19879813
Drug: Pulsed-dose-rate (PDR)
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed-dose-rate (PDR) brachytherapy (PDRBT)
Study: 19879813
Drug: High-dose-rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate (HDR) brachytherapy (HDRBT)
Study: 18443762
Drug: Intensified multi-factorial
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified multi-factorial treatment
Study: 8782754
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (prednisolone reduced to zero over about four months)
Study: 1352363
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 400 mg/kg every 28 days
Study: 6424580
Drug: Induced Hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced Hypertension Chemotherapy (IHC) with a three-drug regimen (adriamycin, 5-FU, mitomycin C or adriamycin, vincristine, carboquone)
Study: 6424580
Drug: Induced Hypertension
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced Hypertension Chemotherapy (IHC) for stomach cancer
Study: 31826896
Drug: Healthy lifestyle
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy lifestyle group sessions (9 weekly sessions)
Study: 24745692
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy in addition to home exercise program (18 days)
Study: 22594581
Drug: Estimated GFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimated GFR (eGFR) below 45 mL/min/1.73 m(2)
Study: 22594581
Drug: eGFR above
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR above 45 mL/min/1.73 m(2)
Study: 15128684
Drug: Postal distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal distribution of a guideline for prescribing asthma medication
Study: 9591542
Drug: Ceftazidime 50
Normalized name: ceftazidime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 50 mg/kg intravenously
Study: 7997065
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extractum (GBE) 160 mg/d combined with memory training
Study: 7997065
Drug: Piracetam 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 2.4 or 4.8 g/d combined with memory training
Study: 7997065
Drug: Piracetam 3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 3.3 g/d combined with normal school teaching and logopedic therapy
Study: 7997065
Drug: Piracetam 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8 g/d combined with speech therapy
Study: 3276453
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine infusion (10, 30, and 50 micrograms/kg/min for 6 min each)
Study: 25315383
Drug: Methotrexate (MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX 50 mg/m(2) administered as a single intramuscular dose)
Study: 25315383
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution administered in a single intramuscular dose)
Study: 23721034
Drug: Basic preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic preventive program (dietary counselling, oral hygiene instructions, fluoride varnish application)
Study: 23721034
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel in trays (additional measure)
Study: 23721034
Drug: 0.2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NaF gel in trays (additional measure)
Study: 23721034
Drug: Daily tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tooth brushing with 1% chlorhexidine gel (additional measure)
Study: 21964172
Drug: MAP0004 (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 (orally inhaled dihydroergotamine)
Study: 19148734
Drug: Oral human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral human immunoglobulin (IGOH) 140, 420, or 840 mg/day
Study: 9576972
Drug: PTH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH and estrogen combination
Study: 23551950
Drug: tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tacrolimus 0.1% ointment
Study: 23551950
Drug: mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: mometasone furoate cream
Study: 21592994
Drug: Baseline CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CRP levels above cohort median (>2.1 mg/L)
Study: 21592994
Drug: Baseline HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HA levels above cohort median (>50.0 ng/mL)
Study: 16903879
Drug: Oral artesunate‐mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artesunate‐mefloquine (AM)
Study: 16903879
Drug: Oral dihydroartemisinin‐piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dihydroartemisinin‐piperaquine (DP)
Study: 15007110
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin daily (intensive therapy)
Study: 15007110
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pravastatin daily (standard therapy)
Study: 9868115
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine and western medicine
Study: 9868115
Drug: Regular medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medicine
Study: 9868115
Drug: Peritoneal cavity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal cavity administration
Study: 7869017
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment after October 1985
Study: 7869017
Drug: Definitive radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Definitive radiotherapy and fat soluble chemotherapy (not utilized in earlier cases)
Study: 2904757
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 to 16 mg once daily)
Study: 2904757
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 40 mg once daily)
Study: 21716297
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg simvastatin daily for 6 months
Study: 13130200
Drug: Fixed-dose fluticasone-salmeterol
Normalized name: FLUTICASONE/SALMETEROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose fluticasone-salmeterol combination (FP/S)
Study: 13130200
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long-acting B2-agonists given separately (TC)
Study: 11702613
Drug: Topical retinol
Normalized name: retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical retinol
Study: 9176691
Drug: Psyllium hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium hydrophilic mucilloid (PHM) 7 gm, twice‐daily added to continuous feeding
Study: 1382251
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Aprotinin (two subgroups with different doses)
Study: 3891455
Drug: Oxazepam Expidet
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam Expidet 30 mg
Study: 30187935
Drug: Ticagrelor 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 0.125 mg/kg
Study: 30187935
Drug: Ticagrelor 0.563
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 0.563 mg/kg
Study: 30187935
Drug: Ticagrelor 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 0.75 mg/kg
Study: 30187935
Drug: Ticagrelor 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 2.25 mg/kg
Study: 30187935
Drug: Ticagrelor (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (0.125, 0.563, or 0.75 mg/kg bid)
Study: 25164709
Drug: Dosing nomogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing nomogram (65 patients)